×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ҩЧѧÑо¿µÄÄÚÈÝÖ®Ò©ÀíЧӦµÄÁ½ÖØÐÔ

2015-11-03
|
»á¼ûÁ¿£º

ҩЧѧÑо¿ÊǶÔÒ©Îï¾ÙÐÐÓÐÓÃÐÔÆÀ¼Û£¬Ä¿µÄÔÚÓÚÆÊÎöÒ©Îï·ÀÖκÍÕï¶Ï¼²²¡µÄ»úÀí£¬Îª¿ª·¢ºÍÆÀ¼ÛÒ©ÎïÌṩ¿ÆÑ§ÒÀ¾Ý¡£

×ðÁú¿­Ê±½¨ÉèÁËÏìÓ¦µÄҩЧѧÑо¿ÊµÑéÄ£×ÓºÍÒªÁ죬´ÓÕûÌ塢ϸ°û¡¢·Ö×ӺͻùÒòˮƽÆÀ¼ÛÐÂҩҩЧѧ£¬´ÓÖÐ̽ÌÖÒ©ÎïµÄ×÷ÓûúÀí¡£Í¨Àý¿ªÕ¹µÄÏîÄ¿ÓУº¿¹Ö×ÁöÒ©ÎïҩЧÊÔÑé¡¢ÐÄѪ¹ÜϵͳҩÎïҩЧѧÆÀ¼Û¡¢¿¹Ñ×Ò©ÎïµÄҩЧѧÆÀ¼Û¡¢½µÑªÌÇÒ©ÎïҩЧѧÆÀ¼Û¡¢ÒÔ¼°»ùÒò¹¤³ÌÀàÒ©ÎïҩЧѧÆÀ¼ÛµÈ¡£

×ðÁú¿­Ê±ÓµÓÐÒ»Ö§×¨ÒµËØÖʺܸߵÄÍŶÓ£¬ÓµÓи»ºñµÄҩЧѧÑо¿ÂÄÀú£¬ÎÒÃǿɳнӻ¯Ñ§Ò©ºÍÉúÎïÊÖÒÕÒ©ÎïµÈҩЧѧÑо¿£¬ÎªÐÂÒ©É걨Ìṩ¿É¿¿µÄÊÔÑéÒÀ¾Ý¡£

ҩЧѧÑо¿


    ÁªÏµ×ðÁú¿­Ê±

    Óʼþ£ºMarketing@medicilon.com.cn

    µç»°:021-58591500



Ò©ÀíЧӦµÄÁ½ÖØÐÔ

1¡¢Ò©ÎïµÄÖÎÁÆÐ§Ó¦

ҩЧѧÑо¿µÄÖ÷ÒªÒªÁìÊÇ£ºÑ¡ÓúÏÊʵ͝ÎïÄ£×ÓºÍÊÓ²ìÒªÁì¾ÙÐÐÔ¤·À»òÖÎÁÆÐ§Ó¦ÊӲ졣¶¯ÎïÄ£×ÓÓ¦ÄÜ·´Ó¦ÁÙ´²¼²²¡µÄ²¡ÀíÐÄÀíѧÀú³Ì¡£ÒÅ´«ÐÔ×Ô¾õÐÔ¼²²¡¶¯ÎïÄ£×ӽϺá£Èç×Ô¾õÐÔ¸ßѪѹ´óÊó£¨SHR£©£¬×ª»ùÒò¶¯ÎïµÈ¡£

ÁÙ´²ÓÃÒ©µÄÄ¿µÄÊÇΪÁËÖÎÁÆÔ¤·À¼²²¡£¬¼õÇᲡÕßµÄÍ´¿à£¬Ò»Ñùƽ³£°ÑÄܹ»µÖ´ïÉÏÊöÄ¿µÄµÄÒ©ÀíЧӦ³ÆÎªÖÎÁÆÐ§Ó¦¡£ÖÎÁÆÐ§Ó¦µÄ±¬·¢¿ÉÒÔÊÇÓÃÒ©¼´Ê±·ºÆð£¬Ò²¿ÉÒÔÔÚ¼¸ÖÜÒÔÖÂÊýÔ·ºÆð£¬ÕâÓë¼²²¡µÄÌØµã£¬Ò©Îï×÷ÓõĻúÖÆºÍÒ©ÎïµÄÌåÄÚÀú³Ì¶¼ÓйØ¡£ÀýÈ磺¹ØÓÚñ²ðïÒ»Á¬×´Ì¬£¬¾²Âö×¢Éä°²¶¨³£ÄܺܿìÏÔЧ£¬µ«±½Í×ÒòÄÆ¿ØÖÆñ²ðïµÄ±¬·¢ÔòÐ輸¸öÔÂÉõÖÁÊýÄêµÄ¼á³ÖÖÎÁÆ¡£Ô¶ÆÚÁÆÐ§ÓÐʱ±È½üÆÚÁÆÐ§¸üÓмÛÖµ£¬ÌØÊâÊÇÊÙÃüÑÓÉ죬éæÃüÂÊϽµÊÇ×îºÃµÄ²ÎÊýÖ¸±ê¡£ÖÎÁÆÐ§Ó¦¾­³£ÊÇÖαêÖα¾¼æ¹ËµÄÀú³Ì£¬ÈçÌÇÄò²¡£¬²¡ÒòÊÇÒȵºÐÔÄÜϽµ£¬Ôö²¹ÍâÔ´ÐÔÒȵºËØÍ¬Ê±Òª¾ÀÕý´úлÔÓÂÒ¡£´Ó½ü»¯Ò½Ñ§Éú³¤µÄ¿´·¨¿´£ºÖ¢×´²¡ÒòÖ®¼äÓÐʱºÜÄÑÓÐÃ÷È·½çÏß¡£Ðí¶à¼²²¡¶¼ÊÇÈ«ÉíÐԵĴúл²¡»ò·Ö×Ó²¡µÈ£¬Ó°Ïìµ½µÄ×éÖ¯Æ÷¹ÙÊǶàÖÖ¶àÑùµÄ£¬ÁÙ´²ÌåÏÖÖØ´ó¶à±ä£¬ÖÎÁÆÊ±±ØÐèÖÜȫ˼Á¿×ÛºÏÆÊÎö¡£


2¡¢Ò©ÎïµÄ²»Á¼·´Ó¦
Ò©Îï×÷ÓÃÒ²Óе¹Ô˵ÄÒ»Ãæ£¬Ôì¹ÊÒâÀíÉú»¯¹¦Ð§ÔÓÂÒ£¬Ò»Ñùƽ³£³ÆÖ®Îª²»Á¼·´Ó¦¡£²»Á¼·´Ó¦³£ºÍÖÎÁÆÐ§Ó¦ËæÍ¬±¬·¢¡£²»Á¼·´Ó¦ÓÖ·ÖΪ£º
¢Ù¸±×÷Ó㬼´ÉÔ΢µÄÖÎÁƼÁÁ¿Ï¾ͱ¬·¢µÄ£¬Ò»Ñùƽ³£Î£º¦Ð¡£¬ÊÇÓÉÓÚÒ©ÎïÑ¡ÔñÐÔµÍÒýÆðµÄ¡£
¢Ú¶¾ÐÔ·´Ó¦£¬¼´½Ï´ó¼ÁÁ¿ÒýÆðÒ©Îï¹ýÁ¿·´Ó¦£¬¶Ô»úÌåÓк¦¡£¸øÒ©ºó¶Ìʱ¼äÄھͱ¬·¢µÄ³ÆÎª¼±ÐÔ¶¾ÐÔ(acutetoxicity)¡£È磺»ÒÓ¤×ÛºÏÖ¢µÈ¡£ÓÐЩ¶¾ÐÔ·´Ó¦±¬·¢¿É³ÙÖÂÊýÔ£¬³ÆÂýÐÔ¶¾ÐÔ£¨chronictoxicity£©¡£ÂýÐÔ¶¾ÐÔÊÇÒ©ÎïÐî»ýÒýÆðµÄ£¬ÈçÒ©ÎïÒýÆð¹Ç÷À»ûÐεÈ¡£ÓÐЩҩÎïÓÐÖ°©(carcinogenesis¡¢Ö»ûÌ¥£¨teratogenesis£©¡¢ÖÂÍ»±ä(mutagenesis)µÄ×÷Ó㬳ÆÎªÂýÐÔ¶¾ÐÔÖеÄÌØÊâ¶¾ÐÔ¡£
¢Ûʧ³£·´Ó¦ºÍÌØÒìÖÊ·´Ó¦£¬´ó´ó¶¼Ò©ÎïµÄ¶¾ÐÔ×÷ÓÃÊÇ¿ÉÒÔÔ¤ÖªµÄ£¬ÓÉÓÚ¶¾ÐÔ×÷ÓÃÒ»Ñùƽ³£ÊÇÒ©Àí×÷ÓõÄÑÓÉ죬¿ÉÊÇÒ²Óв»ÉÙ²»Á¼·´Ó¦ºÍ²î±ðÈ˵ĹýÃôÌåÖÊÓйØ£¬»òÓëÆäÌØÊâµÄÒÅ´«ÌåÖÊÓйØ¡£Ðí¶àÒ©Îï¿ÉÒÔÒýÆð¹ýÃô·´Ó¦¡£È磺¹ýÃôÐÔÐݿˣ¬¹ýÃôÐÔÆ¤Ñ×£¬¹ýÃôÐÔÈÜѪÐÔѪÐé¡£¸ÎÔàµÄËðº¦Ò²ÓйýÃô»úÖÆµÄ±£´æ¡£ÖÂÃôÎïÖÊÓÐʱÊÇÒ©Îï×Ô¼º¡£ÓÐʱÊÇÆäÖеÄÔÓÖÊ£¬ÈôÊÇÊÇÔÓÖÊ£¬ËµÃ÷¸ÃÒ©Æ·ÖÊÁ¿ÓдýÌá¸ß£¬ÈôÊÇÒ©Îï×Ô¼º£¬Ôò¸ÃÒ©ÓпÉÄܱ»ïÔÌ­¡£Ðí¶àÉúÎïȪԴµÄÒ©Æ·³£³ £»áÒò¹ýÃô·´Ó¦¶øÍ¨²»¹ýÆÀÉó£¬ÌØÒìÖÊ·´Ó¦ÊÇÌØÊâµÄÒÅ´«ÌåÖʵ¼Ö²¡È˶ÔÒ©ÎﷴӦˮƽµÄÒ쳣ת±ä¡£
´ó´ó¶¼Ò©ÎïµÄÖ÷Òª²»Á¼·´Ó¦ÊÇ¿ÉÄæµÄ£¬µ«ÓÐЩÊDz»¿ÉÄæµÄ£¬ÆäΣº¦ÐÔ»òЧ¹û½ÏÑÏÖØ£¬Èç°±»ùß°ÀàÒýÆðµÄÉñ¾­ÐÔ¶úÁû£¬¹ãÆ×¿¹ÉúËØÒýÆðµÄ¾úȺʧµ÷¡¢¶þÖØÑ¬È¾£¬ë±½ßÕàºÒýÆðµÄºì°ßÀÇ´¯£¬ÕâЩ³ÆÎªÒ©Ô´ÐÔ¼²²¡¡£ÕâÒªÇóÒ½ÉúÓÃҩѡҩÎÈÖØ£¬ÔÚ¸øÒ©Ê±´úÒª×¢ÖØÊӲ졣
¢ÜºóÒÅЧӦ£¨after effect£©
¢ÝÍ£Ò©·´Ìø£º³¤Ê±¼ä·þÓÃijÖÖÒ©ÎïÖÎÁƼ²²¡£¬ÔÚÖ¢×´»ù±¾¿ØÖÆ»òÁÙ´²ÖÎÓúºóͻȻͣҩ£¬Óɴ˶øÔì³É¼²²¡Äæ×ªµÄÕ÷Ïó³Æ×ö¡°Í£Ò©·´Ìø¡±¡£Ö»¹ÜÖÖÖÖÒ©Îﱬ·¢¡°·´Ìø¡±µÄÔµ¹ÊÔ­Óɲî±ð£¬µ«ÆäЧ¹ûÊÇÒ»ÑùµÄ£¬ÄǾÍÊǼ²²¡Öظ´£¬Ö¢×´¼ÓÖØ£¬Ô½·¢ÄÑÖΡ£È磺½µÑ¹Ò©¡£ 
¸ßѪѹ²¡È˺ã¾Ã·þÓýµÑ¹Ò©¾ÙÐÐÖÎÁÆ£¬µ±ÑªÑ¹½µÖÁÕý³£ºó£¬ÈôÊÇÁ¬Ã¦Í£Ò©£¬ÑªÑ¹¿ÉÔÚ¶ÌÆÚÄÚ´ó·ù¶ÈÉÏÉý£¬ÉõÖÁ¿ÉÁè¼ÝÖÎÁÆÇ°µÄѪѹˮƽ£¬·ºÆðÍ·ÔΡ¢Í·Í´¡¢ÊÓÁ¦Ä£ºýµÈ¸ßѪѹΣÏóÖ¢×´£¬ÑÏÖØÊ±¿É±¬·¢ÄÔѪ¹ÜÆÆËé¡£ÕâÊÇÓÉÓÚͻȻͣҩ£¬Ê¹ÖÐÊಿλ(ÄÔÁ¦)µÄÒ©ÎïŨ¶ÈѸËÙϽµ£¬ÍâÖܽ»¸ÐÉñ¾­Ô˶¯ÔöÇ¿£¬Ê¹È¥¼×ÉöÉÏÏÙËØÊÍ·ÅÔöÌíµÄЧ¹û¡£
¢ÞÒ©ÎïÄÍÊÜ£ºÒ©ÎïÄÍÊÜÐÔÊÇÖ¸ÖØ¸´Ê¹ÓÃÒ»ÖÖÒ©Îïºó£¬ÉíÌå¶Ô¸ÃÒ©ÎïµÄ·´Ó¦½µµÍ£¬ÒÔÖÂÐèÒª¼Ó´óÓÃÒ©Á¿²Å»ªµÖ´ïÔ­ÏȵÄ×÷Óá£ÈçЪϢҩµÄÖØ¸´Ê¹ÓÃÒ×±¬·¢ÄÍÊÜÐÔ£¬ÐªÏ¢Ð§¹û½µµÍ£¬ÐèÒª¼Ó´óÓÃÁ¿²Å»ª±¬·¢Ô­À´µÄЧ¹û¡£ÎüÑÌҲͬÑùµÄÇéÐΣ¬µÚÒ»´ÎÎüÑÌ¿ÉÄܸÐÓ¦²»Ì«ã«Ò⣬¶ø¶à´ÎÎüÑ̺ó²¢ÎÞ²»ÊʸÐÊÜ¡£ÕâÖÖÄÍÊÜÐÔʹ³õÎüÕßÒ»ÎüÔÙÎü£¬×îºóÉÏñ«£¬²¢ÇÒÎüʳÁ¿Ô½À´Ô½´ó¡£
¢ßÒ©ÎïÒÀÀµ£º²¢·ÇΪÁËÒ½ÁÆÐèÒª¶øºã¾Ã»òÖØ¸´Ó¦ÓÃijÖÖÒ©ÎЧ¹û±¬·¢¾«ÉñÉÏ»òÇûÌåÉϵÄÒÀÀµÐÔ£¬ÒÔÖÂÒ»Á¬µØ»òÖÜÆÚµØÇ¿ÁÒÅÎÔ¸ÖØ¸´Ó¦ÓøÃÖÖÒ©Îï¡£Ô­³ÆÒ©ñ«¡£
±¬·¢Ò©ÎïÒÀÀµµÄ³£¼ûÒ©Îï°üÀ¨Ñ»Æ¬ÀࣨÂð·È¡¢º£ÂåÒò¡¢¶ÅÀä¶¡µÈ£©¡¢±½±û°·¡¢¿É¿¨Òò¡¢Ó¡¶È´óÂé¡¢°Í±ÈÍ×ÀࣨËÙ¿ÉÃß¡¢°¢Ã×Íס¢Îì°Í±ÈÍ׵ȣ©¼°ÆäËûЪϢҩ£¨µ¼ÃßÄÜ¡¢ÐªÏ¢Íª£©¡¢¿¹½¹ÂÇÒ©£¨Ãß¶ûͨ¡¢ÀûÃßÄþ¡¢°²¶¨µÈ£©¡¢ÕòÍ´Ò©£¨°¢Ë¹Æ¥ÁÖ¡¢·ÇÄÇÎ÷¶¡¡¢°±»ù±ÈÁֵȣ©¡£
Ò©ÎïÒÀÀµµÄÁÙ´²ÌåÏÖÒòÒ©Îï²î±ð¶ø²î±ð£¬ÆäÅäºÏÌØÕ÷ÊÇ£º¢Ù¾«ÉñÒÀÀµ¡£ÕâÊÇ×îÖ÷ÒªµÄÌØÕ÷¡£ÎªÁË×·ÇóÓÃÒ©ºó¾«ÉñÉϵÄijÖÖÌØÊâ¿ì¸Ð£¬»ò×èÖ¹¶ÏÒ©Ëù±¬·¢µÄÍ´¿à£¬¶ÔÒ©ÎïµÄ¿ÊÇó³ÉΪǿÁÒ¶ø²»¿ÉÒÖÖÆµÄÓûÍû£¬Òò¶øµô±ÛÒ©Îï¶ÔСÎÒ˽¼Ò¡¢¼ÒÍ¥¼°Éç»áµÄΣº¦£¬²»ÔñÊֶεػñµÃÒ©Îï¡£¢ÚÇûÌåÒÀÀµ¡£Îª×èֹͣÓÃÒÑÓÐÒÀÀµÐÔµÄÒ©ÎïËùÒýÆðµÄÇûÌåÖ¢×´¼´Í£Ò©Ö¢×´»ò½ä¶ÏÖ¢×´£¬¶ø±ØÐèÓ¦ÓøÃÒ©»òÓëÆäÒ©Àí×÷ÓÃÏàËÆµÄÒ©Îï¡£½ä¶ÏÖ¢×´ÇáÖØ·×Æç£¬ÇáÕßÖ»¸ÐӦȫ×Ô²»ÊÊ£¬ÖØÕßÔò¿ÉΣ¼°ÉúÃü¡£¢ÛÄÍÒ©ÐÔ¡£ºã¾ÃÖØ¸´Ó¦ÓÃijÖÖÒ©ÎïÖÂÆäЧӦ¼õµÍ£¬Îª»ñµÃÓÃÒ©³õÆÚµÄÒ»ÂÉЧӦ£¬±ØÐèÔöÌí¼ÁÁ¿£¬Æä¼ÁÁ¿¿ÉµÖ´ïͨ³£¼ÁÁ¿µÄ¼¸±¶ÉõÖÁ¼¸Ê®±¶£¬ÕâÑù´óµÄ¼ÁÁ¿ÍùÍùÒýÆðÖж¾¡£

3. Ò©Ô´ÐÔ¼²²¡
Ò©Ô´ÐÔ¼²²¡ÊÇÓ¦ÓÃÒ©Îï²»µ±ËùÒýÆðµÄ¼²²¡¡£³£Ö¸ËðÉËÐÔ¡¢Î£º¦ÐԽϴóÓÖ²»Ò×»Ö¸´µÄÂýÐÔ¶¾ÐÔ·´Ó¦¡£Èç¿ÂÐËÊÏ×ÛºÏÖ¢£¨ ºã¾Ã´ó×ÚÓ¦ÓÃÌÇÆ¤Öʼ¤ËØ£©¡£

Ïà¹ØÄÚÈÝÍÆ¼ö

  • Ò©ÀíѧЧÀÍ

  • ҩЧѧÑо¿

  • ҩЧѧÊÔÑé

  • ÁÙ´²Ç°cro¹«Ë¾

  • ÁÙ´²Ç°Ò©Ð§Ñ§Ñо¿ÄÚÈÝ

Ïà¹ØÐÂÎÅ
Ò©Îï¼ÁÁ¿ÓëЧӦ¹ØÏµ¡¢Ò©Îï×÷ÓûúÖÆÑо¿µÈҩЧѧÑо¿µÄÄÚÈÝ
2015-09-28
ҩЧѧÑо¿µÄ¸øÒ©ÒªÁ죺Ԥ·ÀÐÔ¸øÒ©¡¢ÖÎÁÆÐÔ¸øÒ©¡¢·ÀÖÎÁ¬ÏµµÄ¸øÒ©·½·¨ Ñ¡ÓÃÒ»ÖÖÒÔÉ϶¯Îï¾ÙÐÐҩЧÊÔÑ飬ÿһ·½ÃæÒ©Àí×÷ÓÃҪѡÓÃ2~3ÖÖ¶¯ÎïÄ£×Ó»òÕßϸ°ûÄ£×ÓÀ´×ö¡£
CAR-T Ò©Îï·ÇÁÙ´²ÌåÄÚҩЧѧÑо¿³£ÓõÄÄ£×ÓÓÐÄÄЩ
2021-10-08
ÐÂÐÍ5-HT3ÊÜÌåÅäÌåÓÐÍûÓÃÓÚÖÎÁÆÉñ¾­¾«Éñ¼²²¡ºÍ賦µÀ¼²²¡£¬±¾Ñо¿ÖÐÒ©ÀíҩЧѧÑо¿Í¨¹ý×ðÁú¿­Ê±¾ÙÐÐ
2025-06-12
Droxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligandgated ion channel expressed in for example the brain and the gastrointestinal tract. CSTI-300 as a selective, high affinity 5-HT3 receptor partial agonist. CSTI-300 was examined alongside the selective 5-HT3 receptor antagonist alosetron (which is also currently marketed as a therapeutic for IBS-d). Sub-cutaneous application of 5-hydroxytryptophan (5-HTP; 10 mg/kg) markedly increased the rat¡¯s sensitivity to abdominal contractions. CSTI-300 and Alosetron displayed similar efficacy in a rodent in vivo model of IBS-d, measured by a reduction in colonic sensitivity. The experiments (Rat colon distension model of IBS-d) were carried out by Medicilon. The protocol complied with and was approved by the Institutional Animal Care and Use Committee and Medicilon is accredited by the NIH Office of laboratory Animal Welfare (OLAW) and AAALAC. Experiments (dog behavioural and emesis model) were performed by Medicilon. The protocol for the dog behavioural and emesis model complied with and was approved by the Institutional Animal Care and Use Committee.
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿